- Home
- ARCT vs NGNE Comparison
ARCT vs NGNE Comparison
Compare ARCT & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- NGNE
- Stock Information
- Founded
- ARCT 2013
- NGNE 2003
- Country
- ARCT United States
- NGNE United States
- Employees
- ARCT N/A
- NGNE N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- NGNE Health Care
- Exchange
- ARCT Nasdaq
- NGNE Nasdaq
- Market Cap
- ARCT 526.5M
- NGNE 426.6M
- IPO Year
- ARCT N/A
- NGNE N/A
- Fundamental
- Price
- ARCT $7.34
- NGNE $22.85
- Analyst Decision
- ARCT Buy
- NGNE Strong Buy
- Analyst Count
- ARCT 11
- NGNE 6
- Target Price
- ARCT $38.67
- NGNE $38.50
- AVG Volume (30 Days)
- ARCT 2.2M
- NGNE 259.9K
- Earning Date
- ARCT 11-10-2025
- NGNE 11-13-2025
- Dividend Yield
- ARCT N/A
- NGNE N/A
- EPS Growth
- ARCT N/A
- NGNE N/A
- EPS
- ARCT N/A
- NGNE N/A
- Revenue
- ARCT $97,601,000.00
- NGNE N/A
- Revenue This Year
- ARCT N/A
- NGNE N/A
- Revenue Next Year
- ARCT $26.81
- NGNE N/A
- P/E Ratio
- ARCT N/A
- NGNE N/A
- Revenue Growth
- ARCT N/A
- NGNE N/A
- 52 Week Low
- ARCT $7.26
- NGNE $6.88
- 52 Week High
- ARCT $24.17
- NGNE $43.24
- Technical
- Relative Strength Index (RSI)
- ARCT 26.87
- NGNE 38.74
- Support Level
- ARCT $7.93
- NGNE $23.93
- Resistance Level
- ARCT $9.29
- NGNE $32.02
- Average True Range (ATR)
- ARCT 0.57
- NGNE 3.29
- MACD
- ARCT -0.03
- NGNE -1.03
- Stochastic Oscillator
- ARCT 0.31
- NGNE 3.03
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.